Analyst Ratings For Cara Therapeutics (NASDAQ:CARA)
Today, Seaport Global Securities initiated coverage on Cara Therapeutics (NASDAQ:CARA) with a Buy.
Some recent analyst ratings include
- 1/19/2018-Seaport Global Securities initiated coverage with a Buy rating.
- 1/3/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 11/7/2017-BMO Capital Markets Reiterated Rating of Market Perform.
Recent Insider Trading Activity For Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics (NASDAQ:CARA) has insider ownership of 7.70% and institutional ownership of 58.64%.
- On 11/1/2017 Derek T Chalmers, CEO, sold 16,000 with an average share price of $12.66 per share and the total transaction amounting to $202,560.00.
- On 7/14/2017 Derek T Chalmers, CEO, sold 25,000 with an average share price of $15.05 per share and the total transaction amounting to $376,250.00.
- On 7/14/2017 Frederique Ph.D. Menzaghi, VP, sold 3,000 with an average share price of $15.00 per share and the total transaction amounting to $45,000.00.
- On 6/29/2017 Dean Slagel, Director, sold 250,000 with an average share price of $25.87 per share and the total transaction amounting to $6,467,500.00.
- On 3/31/2017 Ventures Vi Lp Rho, Major Shareholder, bought 500,000 with an average share price of $18.19 per share and the total transaction amounting to $9,095,000.00.
- On 4/20/2016 Frederique Ph.D. Menzaghi, VP, sold 6,000 with an average share price of $9.00 per share and the total transaction amounting to $54,000.00.
- On 3/17/2016 Ventures Vi Lp Rho, Major Shareholder, bought 400,000 with an average share price of $4.87 per share and the total transaction amounting to $1,948,000.00.
Recent Trading Activity for Cara Therapeutics (NASDAQ:CARA)
Shares of Cara Therapeutics closed the previous trading session at 12.53 up +0.09 0.71% with 12.739999771118164 shares trading hands.